This document discusses chiral drug technology and its importance in the pharmaceutical industry. It begins by introducing resolution methods like chromatography and kinetic resolution used to separate chiral compounds. It then discusses resolving agents and how they demonstrate stereoselectivity. Examples are given of major drug products that were originally racemates but are now only marketed as single enantiomers. Chiral drug sales have grown significantly in therapeutic areas like cardiovascular and cancer. The document concludes by stating that chiral technology represents a large commercial opportunity and that consideration of chirality is important in drug research and development due to regulatory guidelines.